RVMD
SellHot AirRevolution Medicines, Inc. · Healthcare · United States · $44.6B · Avg Vol: $361M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT REVOLUTION MEDICINES, INC.
Read
Revolution Medicines, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for RAS-addicted cancers using its proprietary RAS(ON) inhibitor platform. Its innovative approach to directly target oncogenic RAS proteins, historically considered undruggable, positions it at the forefront of cancer drug development. The company is a specialized oncology biotech pioneering novel small molecule inhibitors for a challenging class of cancer targets.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 35.4M | 11.6M | 0 | 0 | -67.3% | — | 169.7M | 1.2B | 222.0% |
| EPS | -1.31 | -3.86 | -3.58 | -5.95 | — | -8.86 | -9.73 | -5.95 | — |
| Shares | 212.6M | 164.7M | 185.9M | 197.0M | -7.3% | 214.3M | — | — | — |
| Debt | 64.2M | 87.9M | 135.8M | 158.7M | 35.2% | 1.2B | — | — | — |
| Equity | 685.2M | 1.8B | 2.3B | 1.6B | 33.5% | — | — | — | — |
| Op CF | -224.4M | -350.6M | -557.4M | -897.7M | — | -1.2B | — | — | — |
| Inv CF | -24.1M | -342.6M | -554.4M | 118.1M | — | — | — | — | — |
| Fin CF | 301.4M | 1.2B | 959.4M | 621.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RVMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc.(you) | $44.6B | 23 | Sell |
| MRNA | Moderna, Inc. | $55.1B | 28 | Sell |
| ALNY | Alnylam Pharmaceuticals, Inc. | $31.7B | 30 | Sell |
| INSM | Insmed Incorporated | $25.9B | 13 | Strong Sell |
| BBIO | BridgeBio Pharma, Inc. | $15.0B | 22 | Sell |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $12.0B | 25 | Sell |
| AXSM | Axsome Therapeutics, Inc. | $10.4B | 24 | Sell |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | 24 | Sell |
| MDGL | Madrigal Pharmaceuticals, Inc. | $12.3B | 30 | Sell |
| PRAX | Praxis Precision Medicines, Inc. | $9.6B | 21 | Sell |
Peer medians: ROE -30.9% · P/E 25.1x · Gross margin 58.3%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.